Septerna Stock

www.septerna.com/Healthcare / BioTech & PharmaFounded: 2022Funding to Date: $225MM

Septerna, founded in 2022, is a biotechnology company that strives to discover and advance novel small-molecule medicines targeting G protein-coupled receptors through its Native Complex platform. The company's mission is to discover, develop, and commercialize medicines that improve the lives of patients by combining GPCR drug targets with small molecule drug discovery technologies. Septerna is headquartered in San Francisco, California.

Register for Details

For more details on financing and valuation for Septerna, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Septerna.

Register Today

Team

Management Team

Jeffrey Finer Ph.D
Co-Founder & Chief Executive Officer
Liz Bhatt
Chief Operating Officer
Samira Shaikhly
Chief People Officer
Ali Masoudi
Co-Founder & Staff Scientist
Arthur Christopoulos Ph.D
Co-Founder
Patrick Sexton Ph.D
Co-Founder
Robert Lefkowitz MD
Co-Founder

Board Members

Abraham Bassan
Samsara BioCapital
Alan Ezekowitz MD
Third Rock Ventures
Jeffrey Tong Ph.D
Third Rock Ventures

Other companies like Septerna in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Septerna snags $150M series B for pipeline of GPCR therapies tackling hard-to-drug targets
Septerna has secured $150 million in a series B fundraise, money that will go toward two newly unveiled programs including moving its first G-protein-coupled receptor (GPCR) drug into the clinic.
Updated on: Oct 3, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.